07:41 AM EST, 11/15/2024 (MT Newswires) -- Novavax's ( NVAX ) version of the Nuvaxovid COVID-19 vaccine targeting the Omicron JN.1 subvariant has been approved for use in the UK, the country's Medicines and Healthcare products Regulatory Agency said Friday

The vaccine is approved for use in those aged 12 or older, the regulatory body said.

The marketing authorization was granted on Wednesday, the regulator said.